Clinical Trial Update: Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) [Phase 3]

View source ↗

Summary

Phase 3 trial results show safety and efficacy of CSL Behring's intravenous immunoglobulin IgPro10 in patients with primary immunodeficiencies, including X-link…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Common Variable Immunodeficiency
• Hypogammaglobulinemia
• X-linked Agammaglobulinemia

Drugs mentioned

• IgPro10 (intravenous immunoglobulin)

Snippet

Sponsor: CSL Behring | Conditions: Agammaglobulinemia, IgG Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2012-10-26